Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07283263 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

A Phase 1 study of Healthy Volunteers, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
106
Enrollment target
1
Study location

NCT07283263 is a Phase 1 study of Healthy Volunteers that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 106 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07283263, a Phase 1 study of Healthy Volunteers, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
106 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on BMS-986521 exposure.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG BMS-985521

Study Locations (1)

California

  • CenExel ACT (Formerly Anaheim Clinical Trials; LLC) - Anaheim

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2025-12-23
Est. Completion 2026-11-17
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT07283263

The ClinicalTrials.gov registry entry for NCT07283263 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (78% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07283263 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07283263 about?

NCT07283263 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.". The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on BMS-986521 exposure.

What is the current status of trial NCT07283263?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2025-12-23. Estimated completion is 2026-11-17.

What conditions does trial NCT07283263 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT07283263?

The interventions under investigation include: Placebo (OTHER), BMS-985521 (DRUG).

Who is sponsoring clinical trial NCT07283263?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07283263 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.